According to the technology consulting firm, the platform uses artificial intelligence (AI) to enable the clients to store and process their data, as well as to share across the company's collaborative teams.
In addition, Accenture Life Sciences’ platform will give users the option to be connected to another company’s network to access data, aiming to facilitate collaboration between partners.
Kevin Julian, senior managing director at Accenture, told us that the company presented Intient in a series of meetings with clients and received 'requests for follow up' from every company in attendance.
Intient comes with an open software architecture, which will allow modifications and includes four of Accenture’s already established platforms:
- The Accenture research platform (now Intient Research platform), which connects researchers with software and service providers for data sharing.
- The Accenture Life Sciences Cloud (now Intient Clinical platform) for data storage.
- The PV First (now Intient Pharmacovigilance platform) provides analytics for the pharmacovigilance process.
- The Intelligent Patient Platform (now Intient Patient Platform) to support patients participating on clinical trials.
According to Accenture's senior managing director, the company also has plans to expand Intient’s functions in the future.
The company stated that the product answers the needs discovered in a survey by International Data Corporation (IDC) Health Insights, which found that 51% of 126 pharmaceutical and biotechnology executives do not have a clear way to connect, share, and analyse data across the organization.
Commenting on that, Alan Louie, research director for Life Sciences at IDC Health Insights, said in a statement, “Clearly, there is work to do for the industry to realize the potential of end-to-end connectivity, and solutions such as Accenture Intient could prove to be a step forward in those efforts.”